Document Detail

Ambulatory blood pressure values in the Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial (ONTARGET).
MedLine Citation:
PMID:  23071122     Owner:  NLM     Status:  MEDLINE    
In the Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial, telmisartan (T; 80 mg daily) and ramipril (R; 10 mg daily) caused similar clinic blood pressure (BP) reductions, with a similar incidence of cardiovascular and renal events. The R+T combination lowered clinic BP somewhat more with no further cardiovascular or renal protection. The aim of this substudy was to see whether these clinic BP changes reflected the changes of 24-hour BP, a BP with a better prognostic value. In 422 patients in whom 24-hour BP monitoring was performed either before or after 6 to 24 months of treatment, demographic and clinical characteristics were similar in the 3 treated groups. Twenty-four-hour systolic BP was similarly reduced by R (-2.0 mm Hg) and T (-2.1 mm Hg), whereas the reduction was more than twice as large in the T+R group (-5.3 mm Hg), which showed a lower on-treatment 24-hour BP also in additional patients (n=408) in whom ambulatory BP was performed only on-treatment. Twenty-four-hour systolic BP was ≈ 14 mm Hg lower than clinic systolic BP at baseline, whereas during treatment the 2 values became progressively closer as clinic systolic BP was more tightly controlled and superimposable when clinic systolic BP was <120 mm Hg. Similar results were obtained for diastolic BP. These findings provide evidence on the relationship of clinic and ambulatory BP target drug treatment. They also show that in the Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial, failure of the R+T combination to enhance cardiovascular and renal protection was not because of inability to more effectively control daily life BP.
Giuseppe Mancia; Gianfranco Parati; Grzegorz Bilo; Peggy Gao; Robert Fagard; Josep Redon; Istvan Czuriga; Martin Polák; Josè M Ribeiro; Ramiro Sanchez; Bruno Trimarco; Paolo Verdecchia; Walter van Mieghem; Koon Teo; Peter Sleight; Salim Yusuf
Publication Detail:
Type:  Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't     Date:  2012-10-15
Journal Detail:
Title:  Hypertension     Volume:  60     ISSN:  1524-4563     ISO Abbreviation:  Hypertension     Publication Date:  2012 Dec 
Date Detail:
Created Date:  2012-11-15     Completed Date:  2013-02-07     Revised Date:  2014-01-09    
Medline Journal Info:
Nlm Unique ID:  7906255     Medline TA:  Hypertension     Country:  United States    
Other Details:
Languages:  eng     Pagination:  1400-6     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Angiotensin-Converting Enzyme Inhibitors / pharmacology,  therapeutic use*
Antihypertensive Agents / pharmacology,  therapeutic use*
Benzimidazoles / pharmacology,  therapeutic use*
Benzoates / pharmacology,  therapeutic use*
Blood Pressure / drug effects*
Blood Pressure Monitoring, Ambulatory
Drug Therapy, Combination
Hypertension / drug therapy*
Longitudinal Studies
Middle Aged
Ramipril / pharmacology,  therapeutic use*
Treatment Outcome
Reg. No./Substance:
0/Angiotensin-Converting Enzyme Inhibitors; 0/Antihypertensive Agents; 0/Benzimidazoles; 0/Benzoates; L35JN3I7SJ/Ramipril; U5SYW473RQ/telmisartan
Comment In:
Hypertension. 2013 Feb;61(2):e16   [PMID:  23444461 ]
Hypertension. 2013 Feb;61(2):e15   [PMID:  23248148 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Nucling, a novel protein associated with NF-?B, regulates endotoxin-induced apoptosis in vivo.
Next Document:  Long-Term Consequences of Uninephrectomy in Male and Female Rats.